헤더 로고

• All
• March 26 (Thu)
• March 27 (Fri)
• March 28 (Sat)

Day 1: March 26 (Thu)

• Advances and Insights in Molecular Monitoring for Myeloproliferative Neoplasms Hsin-An Hou
  National Taiwan University Hospital, Taiwan CV Abstract
• Evolving Treatment Paradigms in Early Myelofibrosis Winnie Teo
  Alexandra Hospital, Singapore CV Abstract
• Optimizing Treatment Strategies in Higher MF and Beyond Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 1: March 26 (Thu)

• Recent Advances in the Diagnosis and Management of Acquired Hemophilia A Shin Young Hyun
  Yonsei University College of Medicine, Korea CV Abstract
• Clinical Advances and Challenges in Gene Therapy for Hemophilia Ben Samelson-Jones
  The Children's Hospital of Philadelphia, USA CV Abstract
• Role of Bispecific Antibody in Hemophilia Claude Négrier
  University of Lyon, France CV Abstract

Day 1: March 26 (Thu)

• Integration of MRD and Genetics as a Therapeutic Guidepost in ALL Anthony Moorman
  Newcastle University, UK CV Abstract
• Modern Immunotherapeutics in B-ALL: BiTEs, ADCs, and Beyond Jae-Ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV
• Optimizing Frontline Therapy in Ph+ ALL: The Role of Ponatinib and Beyond Nicholas J. Short
  The University of Texas MD Anderson Cancer Center, USA CV Abstract

Day 1: March 26 (Thu)

• Mantle Cell Lymphoma Jaewon Hyung
  University of Ulsan College of Medicine, Korea CV Abstract
• Chronic Lymphocytic Leukemia Jongheon Jung
  National Cancer Center, Korea CV Abstract
• Marginal Zone Lymphoma Sang-A Kim
  Seoul National University College of Medicine, Korea CV Abstract

Day 1: March 26 (Thu)

• What Makes a Stem Cell and How Does It Go Bad John E. Dick
  University Health Network, Canada CV Abstract

Day 1: March 26 (Thu)

• Mechanism-Driven Combination Targeted Therapies for Diffuse Large B-cell Lymphoma Wyndham H. Wilson
  National Cancer Institute, USA CV Abstract

Day 1: March 26 (Thu)

• Recent Insights on DLBCL Treatment: Focused on Polatuzumab and Glofitamab Matthew Matasar
  Rutgers Cancer Institute, USA CV

Day 1: March 26 (Thu)

• Immunoglobulin Replacement in the Era of Cellular and Bispecific Therapies Ja Min Byun
  Seoul National University College of Medicine, Korea CV

Day 1: March 26 (Thu)

• Changing the Survival Landscape in RRMM with Novel ADC Sung-Hoon Jung
  Chonnam National University Medical School, Korea CV Abstract

Day 1: March 26 (Thu)

• Epcoritamab in 3L+ DLBCL: Updates on Clinical Trial and Real World Data in the Evolving DLBCL Treatment Pathway William Townsend
  University College London Hospitals NHS Foundation Trust, UK CV Abstract

Day 1: March 26 (Thu)

• Advancing CML Treatment with Clinical Insights on Asciminib Eri Matsuki
  Keio University School of Medicine, Japan CV Abstract

Day 1: March 26 (Thu)

• The Current State of Transplantation for Aplastic Anemia in Vietnam Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Recent Update of the Treatment of Aplastic Anemia in Thailand Ponlapat Rojnuckarin
  Chulalongkorn University, Thailand CV Abstract
• PNH Management in Korea: Therapeutic Options, Access and Real-World Outcomes Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV

Day 1: March 26 (Thu)

• Integrating Comprehensive Geriatric Assessment into Hematology Practice: Identifying Frailty and Optimizing Care for Older Adults Jung-Yeon Choi
  Seoul National University Bundang Hospital, Korea CV Abstract
• Redefining Risk in Elderly AML: A Geriatric Assessment-Based Approach Byung Sik Cho
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Psycho-Oncological Interventions in Geriatric Hematology: Enhancing Quality of Life Juhee Cho
  Samsung Comprehensive Cancer Center, Sungkyunkwan University, Korea CV Abstract

Day 1: March 26 (Thu)

• Engineered NK Cells for Optimal Anti-Tumor Immunotherapy Challice Bonifant
  Johns Hopkins University School of Medicine, USA CV Abstract
• Lessons from Hemophagocytic Lymphohistiocytosis: Taming the Cytokine Storm in CAR-T Cell Therapy Michael B. Jordan
  Cincinnati Children’s Hospital Medical Center, USA CV
• Tumor-Marrow Axis: Myeloid Reprogramming from Suppression to Activation Seunghee Kim-Schulze
  Icahn School of Medicine at Mount Sinai, USA CV Abstract

Day 1: March 26 (Thu)

• FLT3-Positive AML Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV Abstract
• B-cell ALL with HIgh Risk Features in Adults Dong Won Baek
  Kyungpook National University School of Medicine, Korea CV Abstract
• Understanding and Clinical Approach to Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Hee Young Ju
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 1: March 26 (Thu)

• Insights into DDX41 Mutations: Relatively Common Genetic Aberrations in Korean MDS Patients Hongtae Kim
  Ulsan National Institute of Science and Technology (UNIST), Korea CV Abstract
• Few Drug Approvals in MDS: Lessons and Insights from a Decade of Clinical Trials Maximilian Stahl
  Yale University School of Medicine, USA CV Abstract
• Clinical Approach to Relapsed or Refractory Lower-Risk Myelodysplastic Syndromes Valeria Santini
  University of Florence, Italy CV Abstract

Day 1: March 26 (Thu)

• Recent Advances in the Genetics of Telomere Biology Disorders Sharon A. Savage
  National Institutes of Health, USA CV Abstract
• Clonal Hematopoiesis in the Short Telomere Syndromes Kristen E. Schratz
  Johns Hopkins University School of Medicine, USA CV Abstract
• Current Status of Telomere Biology Disorders in Inherited Bone Marrow Failure Inderjeet Dokal
  Queen Mary University of London, UK CV Abstract

Day 1: March 26 (Thu)

• Next-Generation Effector Cells in Myeloma Immunotherapy Hyunsoo Cho
  Seoul National University College of Medicine, Korea CV Abstract
• Natural Killer Cell-Based Immunotherapy in Multiple Myeloma Seung-Hwan Lee
  University of Ottawa, Canada CV Abstract
• Preclinical Optimization of T Cell Redirected Therapy Marta Chesi
  Mayo Clinic, USA CV Abstract

Day 1: March 26 (Thu)

• Procedures and Interpretation of Bone Marrow Examination Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV Abstract
• Diagnostic and Monitoring Approaches Focused on Minimal Residual Disease Miyoung Kim
  University of Ulsan College of Medicine, Korea CV Abstract
• Laboratory Tests Performed in Blood Bank before and after Hematopoietic Stem Cell Transplantation Dong Wook Jekarl
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Multi-Omic Precision Medicine including Functional Drug Screening to Optimize Treatment for Acute Myeloid Leukemia Pamela S. Becker
  City of Hope, USA CV Abstract
• Novel Immunotherapeutic Strategies: Preclinical Insights Ji Eun Jang
  Yonsei University College of Medicine, Korea CV Abstract
• Developing Next-Generation Cell Therapy Approaches for AML Paulina Velasquez
  St. Jude Children’s Research Hospital, USA CV Abstract
• Emerging Ex-vivo Drug Sensitivity Platforms Daehun Kwag
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Microbiome-Driven Precision Medicine in CAR-T Cell Therapy in Hematology Christoph K. Stein-Thoeringer
  University Clinic Tübingen, Germany CV Abstract
• Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang
  Kangwon National University, Korea CV Abstract
• Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled
  Memorial Sloan Kettering Cancer Center, USA CV Abstract

Day 2: March 27 (Fri)

• A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak
  City of Hope, USA CV Abstract
• Paradigm Shift in the Treatment of Diffuse Large B-cell Lymphoma: The Era of Bispecific Antibodies Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Toward a Paradigm Shift in Personalized Therapies for DLBCL Using Liquid Biopsies Ash A. Alizadeh
  Stanford University, USA CV Abstract

Day 2: March 27 (Fri)

• Iron Deficiency & Iron Metabolism Jeong-Ok Lee
  Seoul National University College of Medicine, Korea CV Abstract
• Hereditary Hemolytic Anemia Heewon Chueh
  Inje University College of Medicine, Korea CV Abstract
• Cold Agglutinin Disease Dae-Ho Choi
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• The Past, Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar
  National Institutes of Health, USA CV Abstract

Day 2: March 27 (Fri)

• Triple Targeting in Myelofibrosis with Momelotinib: Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Clinical Evidence of Romiplostim in Aplastic Anemia: Korean Expert Recommendations Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Daratumumab in the Emerging Landscape of Functional High-Risk Multiple Myeloma Andrew Spencer
  Alfred Hospital, Australia CV

Day 2: March 27 (Fri)

• Early CAR-T Intervention in DLBCL: Clinical Advances and Real-World Effectiveness of Axi-cel Mark Dowling
  Peter MacCallum Cancer Centre, Australia

Day 2: March 27 (Fri)

• How to Optimize CML Treatment in 2026: ELN 2025 and Molecular Guidance Elias Jabbour
  MD Anderson Cancer Center, USA CV Abstract

Day 2: March 27 (Fri)

• Operational Wisdom in CAR T Jürgen Kuball
  University Medical Center Utrecht, The Netherlands CV Abstract
• Korean CAR T-cell Registry: Inauguration and the Current Status of CAR T-cell Therapy in Korea Ji Hyun Lee
  Dong-A University College of Medicine, Korea CV Abstract
• CAR T-cell Therapy for Primary and Secondary CNS Lymphomas Andrés J. M. Ferreri
  University Vita-Salute San Raffaele, Italy CV Abstract
• CAR T-cell Therapy in Primary and Secondary CNS Lymphomas in Korea Hyungwoo Cho
  Asan Medical Center, University of Ulsan College of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• Genomics and Transplant Strategies in Pediatric Myeloid Malignancies Jae Wook Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Virus-Specific and Next-Generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine M. Bollard
  Children’s National Hospital and The George Washington University, USA CV Abstract
• Cancer Survivorship after the Cure of Childhood Blood Cancers: Risk Based Surveillance Sharon M. Castellino
  Emory University School of Medicine, USA CV Abstract

Day 2: March 27 (Fri)

• Stem Cells in Human AML Ravindra Majeti
  Stanford University, USA CV Abstract
• Evolving Frontiers in Targeted Therapy: Menin Inhibition in AML Eytan M. Stein
  Memorial Sloan Kettering Cancer Center, USA CV Abstract
• HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia
  The University of Texas MD Anderson Cancer Center, USA CV

Day 2: March 27 (Fri)

• Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi
  Digital Healthcare Partners (DHP), Korea CV
• Wise Hematology Life: Practical Integration of Large Language Models and Agentic AI into Clinical Research Jeong-Moo Lee
  Ewha Womans University College of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper
  Imperial College Health Care NHS Trust, UK CV Abstract
• A New Chapter in ITP Management - Updated Trials Jun Ho Jang
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi
  Johns Hopkins University School of Medicine, USA CV

Day 2: March 27 (Fri)

• AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis
  National and Kapodistrian University of Athens, Greece CV Abstract
• Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung
  Mayo Clinic, USA CV Abstract
• Novel Biological and Clinical Insights into POEMS Syndrome: Pathophysiology and Real-World Treatment Outcomes from Japan Emiko Sakaida
  Chiba University Hospital, Japan CV Abstract

Day 2: March 27 (Fri)

• CRS and ICANS: Early Detection and Personalized Management Jinchul Kim
  Inha University College of Medicine, Korea CV Abstract
• Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun
  Seoul National University College of Medicine, Korea CV Abstract

Day 3: March 28 (Sat)

• Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi
  Mie University Graduate School of Medicine, Japan CV Abstract
• Advances in the Diagnosis and Treatment of NK/T-cell Lymphoma: Perspectives and Team Experience Huangming Hong
  Sichuan Cancer Hospital, China CV Abstract
• Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 3: March 28 (Sat)

• Ethnic Disparities in Germline Variants of Myeloid Malignancies Young-Uk Cho
  University of Ulsan College of Medicine, Korea CV Abstract
• Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers
  Erasmus MC Cancer Institute, The Netherlands CV Abstract
• Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager
  Mayo Clinic, USA CV Abstract

Day 3: March 28 (Sat)

• Immunological Landscape of CML Kyung-Mi Lee
  Korea University College of Medicine, Korea Abstract
• Translating Single-Cell Biology into Clinically Actionable Protein Biomarkers in CML Sin Tiong Ong
  Duke-NUS Medical School, Singapore CV Abstract
• Drug Combination to Overcome Resistance in CML Delphine Rea
  Saint-Louis University Hospital, France CV Abstract

Day 3: March 28 (Sat)

• Vaccination and Infection Prevention Seong Jin Choi
  Seoul National University College of Medicine, Korea CV Abstract
• Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park
  Chonnam National University Medical School, Korea CV Abstract
• Chemotherapy-Induced Peripheral Neuropathy Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea CV

Day 3: March 28 (Sat)

• High-Risk Multiple Myeloma in 2026: Early Intervention, MRD-Driven Therapy, and Beyond Philippe Moreau
  University Hospital of Nantes, France CV